Core promoter sequence of SEMG I spans between the two putative GATA-1 binding domains and is responsive to IL-4 and IL-6 in myeloma cells.
Semenogelin (SEMG) I is a cancer-testis antigen expressed in myeloma cells. SEMG I expression is upregulated by IL-4, IL-6 and 5-azacytidine. In this study, we set out to define the core promoter sequence needed for the expression of SEMG I in myeloma cells. We found that nucleotide sequences spanning the two putative GATA-1 binding domains are vital for the primary regulation of SEMG I promoter function while the other parts of the promoter sequence are responsible for the fine adjustment of the core promoter function. The core promoter sequence is responsive to the enhancing effect of IL-4 and IL-6.
Zhang
Yana
Y
Cancer Research Program, Harrington Regional Medical Center, Amarillo, United States.
Wang
Zhiqing
Z
Zhang
Jian
J
Lim
Seah H
SH
D001483:Base Sequence; D001665:Binding Sites; D045744:Cell Line, Tumor; D015500:Chloramphenicol O-Acetyltransferase / Q000235:genetics; D017931:DNA Primers; D050982:GATA1 Transcription Factor / Q000378:metabolism*; D006801:Humans; D015847:Interleukin-4 / Q000494:pharmacology*; D015850:Interleukin-6 / Q000494:pharmacology*; D016133:Polymerase Chain Reaction; D011401:Promoter Regions, Genetic; D029607:Seminal Vesicle Secretory Proteins / Q000235:genetics*
D017931:DNA Primers; D050982:GATA1 Transcription Factor; C494688:GATA1 protein, human; D015850:Interleukin-6; D029607:Seminal Vesicle Secretory Proteins; C424482:seminal vesicle-specific antigen; D015847:Interleukin-4; D015500:Chloramphenicol O-Acetyltransferase